No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity

被引:1
作者
Nomoto, Hidetoshi [1 ]
Kutsuna, Satoshi [1 ]
Okuma, Kazu [3 ]
Kuramitsu, Madoka [3 ]
Tezuka, Kenta [3 ]
Ikebe, Emi [3 ]
Saito, Sho [1 ,2 ]
Kinoshita, Noriko [1 ,2 ,4 ]
Terada, Mari [1 ]
Endo, Mio [1 ]
Suzuki, Tetsuya [1 ,2 ]
Miyazato, Yusuke [1 ]
Nakamoto, Takato [1 ]
Inada, Makoto [1 ]
Hamaguchi, Isao [3 ]
Ohmagari, Norio [1 ,2 ,4 ]
机构
[1] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan
[2] Tohoku Univ, Emerging & Reemerging Infect Dis, Grad Sch Med, Sendai, Miyagi, Japan
[3] Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, Tokyo, Japan
[4] Natl Ctr Global Hlth & Med, Antimicrobial Resistance Clin Reference Ctr, Tokyo, Japan
关键词
Coronavirus; 2019; Severe acute respiratory syndrome; coronavirus; 2; RNA; Convalescent plasma; Passive immunization;
D O I
10.1016/j.jiac.2021.01.004
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Convalescent plasma transfusion (CPT), a potential therapy for coronavirus disease 2019 (COVID-19), requires strict quality control of the donor blood. Whether to confirm the disappearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA (RNAemia) in convalescent donor blood or not is unclear. Reports recommending the proof of viral disappearance from the blood are controversial. Foreseeing CPT in treating COVID-19 patients in Japan, we investigated RNAemia in 100 convalescent donors with mild, moderate, and severe COVID-19. Methods: Between April 30 and July 30, 2020, we measured RNAemia in the plasma samples of donors with resolved COVID-19. Data on patients' demographics, comorbidities, pneumonia, treatment, and real-time polymerase chain reaction results for SARS-CoV-2 were collected. Date of onset of initial symptoms or date of positive testing (for asymptomatic patients) were self-reported by the patients. Disease severity was defined as: no, mild, moderate oxygen demand, or severe (requiring mechanical ventilation). Results: Of 100 donors (58 males [58.0%]; median age, 47 [range 22-69] years) screened as of July 30, 2020, 77 (77.0%); 19 (19.0%); and 4 (4.0%) had mild, moderate, and severe disease, respectively. Median time between onset and testing was 68.5 (range, 21-167) days. SARS-CoV-2 RNA was not detected in any of the plasma samples. Conclusion: RNAemia was not found in recovered COVID-19 patients at least 21, 27, and 57 days after the onset of mild, moderate, and severe symptoms. Our study may contribute to determining a suitable time for collecting convalescent plasma from COVID-19 patients and to future CPT use. (c) 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:653 / 655
页数:3
相关论文
共 12 条
[1]   The convalescent sera option for containing COVID-19 [J].
Casadevall, Arturo ;
Pirofski, Liise-Anne .
JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (04) :1545-1548
[2]   Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations [J].
Chang, Le ;
Zhao, Lei ;
Gong, Huafei ;
Wang, Lunan ;
Wang, Lan .
EMERGING INFECTIOUS DISEASES, 2020, 26 (07) :1631-1633
[3]  
Hogan CA, 2020, CLIN INFECT DIS
[4]   Post-donation COVID-19 identification in blood donors [J].
Kwon, So-Yong ;
Kim, Eun-Jin ;
Jung, Yu Soek ;
Jang, Jin Sung ;
Cho, Nam-Sun .
VOX SANGUINIS, 2020, 115 (08) :601-602
[5]   Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial [J].
Li, Ling ;
Zhang, Wei ;
Hu, Yu ;
Tong, Xunliang ;
Zheng, Shangen ;
Yang, Juntao ;
Kong, Yujie ;
Ren, Lili ;
Wei, Qing ;
Mei, Heng ;
Hu, Caiying ;
Tao, Cuihua ;
Yang, Ru ;
Wang, Jue ;
Yu, Yongpei ;
Guo, Yong ;
Wu, Xiaoxiong ;
Xu, Zhihua ;
Zeng, Li ;
Xiong, Nian ;
Chen, Lifeng ;
Wang, Juan ;
Man, Ning ;
Liu, Yu ;
Xu, Haixia ;
Deng, E. ;
Zhang, Xuejun ;
Li, Chenyue ;
Wang, Conghui ;
Su, Shisheng ;
Zhang, Linqi ;
Wang, Jianwei ;
Wu, Yanyun ;
Liu, Zhong .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05) :460-470
[6]   SARS-CoV-2 RNAemia in a Healthy Blood Donor 40 Days After Respiratory Illness Resolution [J].
Pham, Tho D. ;
Huang, ChunHong ;
Wirz, Oliver F. ;
Roltgen, Katharina ;
Sahoo, Malaya K. ;
Layon, Arlene ;
Pandey, Suchitra ;
Foung, Steven K. ;
Boyd, Scott D. ;
Pinsky, Benjamin A. .
ANNALS OF INTERNAL MEDICINE, 2020, 173 (10) :853-854
[7]   Convalescent plasma transfusion for the treatment of COVID-19: Systematic review [J].
Rajendran, Karthick ;
Krishnasamy, Narayanasamy ;
Rangarajan, Jayanthi ;
Rathinam, Jeyalalitha ;
Natarajan, Murugan ;
Ramachandran, Arunkumar .
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (09) :1475-1483
[8]  
Salazar E, 2020, AM J PATHOL, V190, P1680, DOI [10.1016/j.ajpath.2020.10.008, 10.1016/j.ajpath.2020.05.014]
[9]   Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan [J].
Shirato, Kazuya ;
Nao, Naganori ;
Katano, Harutaka ;
Takayama, Ikuyo ;
Saito, Shinji ;
Kato, Fumihiro ;
Katoh, Hiroshi ;
Sakata, Masafumi ;
Nakatsu, Yuichiro ;
Mori, Yoshio ;
Kageyama, Tsutomu ;
Matsuyama, Shutoku ;
Takeda, Makoto .
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2020, 73 (04) :304-307
[10]  
U.S. Food & Drug Administration, UPD INF BLOOD EST RE